Stocks
Amylyx Pharmaceuticals Financial Statements (AMLX) |
||||||||||
| Amylyx Pharmaceuticalssmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 11.05.2023 | 10.08.2023 | 09.11.2023 | 22.02.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 71.4 | 98.2 | 102.7 | 108.4 | 88.6 | 398.0 | |||
| Operating Income, bln rub | -2.05 | 20.2 | 18.7 | 1.93 | -122.1 | -81.3 | ||||
| EBITDA, bln rub | ? | -2.05 | 20.5 | 19.0 | 2.24 | -121.8 | -80.1 | |||
| Net profit, bln rub | ? | 1.57 | 22.1 | 20.9 | 4.73 | -118.8 | -71.1 | |||
| OCF, bln rub | ? | -5.07 | 8.61 | -5.17 | 13.6 | -0.489 | 16.5 | |||
| CAPEX, bln rub | ? | 0.250 | 0.278 | 0.357 | 0.356 | 0.067 | 1.06 | |||
| FCF, bln rub | ? | -5.32 | 8.33 | -5.53 | 13.2 | -0.556 | 15.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 68.2 | 72.4 | 78.8 | 97.2 | 94.1 | 342.4 | ||||
| Cost of production, bln rub | 5.28 | 5.58 | 5.22 | 9.36 | 116.7 | 136.9 | ||||
| R&D, bln rub | 24.2 | 29.0 | 30.0 | 44.9 | 36.3 | 140.3 | ||||
| Interest expenses, bln rub | 3.46 | 0.000 | 0.000 | 3.46 | 0.000 | 3.46 | ||||
| Assets, bln rub | 408.0 | 453.6 | 466.6 | 517.5 | 417.5 | 417.5 | ||||
| Net Assets, bln rub | ? | 352.6 | 386.4 | 418.4 | 433.4 | 324.4 | 324.4 | |||
| Debt, bln rub | 5.79 | 5.29 | 4.77 | 4.24 | 3.69 | 3.69 | ||||
| Cash, bln rub | 345.7 | 357.3 | 355.0 | 371.4 | 373.3 | 373.3 | ||||
| Net debt, bln rub | -339.9 | -352.0 | -350.3 | -367.1 | -369.6 | -369.6 | ||||
| Ordinary share price, rub | 29.3 | 21.6 | 18.3 | 14.7 | 2.84 | |||||
| Number of ordinary shares, mln | 66.7 | 67.2 | 67.4 | 67.4 | 67.9 | 67.9 | ||||
| Market cap, bln rub | 1 957 | 1 450 | 1 234 | 992 | 193 | 0 | ||||
| EV, bln rub | ? | 1 618 | 1 098 | 884 | 625 | -177 | -370 | |||
| Book value, bln rub | 353 | 386 | 418 | 433 | 324 | 324 | ||||
| EPS, rub | ? | 0.02 | 0.33 | 0.31 | 0.07 | -1.75 | -1.05 | |||
| FCF/share, rub | -0.08 | 0.12 | -0.08 | 0.20 | -0.01 | 0.23 | ||||
| BV/share, rub | 5.29 | 5.75 | 6.21 | 6.43 | 4.78 | 4.78 | ||||
| EBITDA margin, % | ? | -2.87% | 20.9% | 18.5% | 2.06% | -137.4% | -20.1% | |||
| Net margin, % | ? | 2.20% | 22.5% | 20.3% | 4.36% | -134.0% | -17.9% | |||
| FCF yield, % | ? | -7.50% | -6.26% | -4.28% | 1.08% | 8.01% | ||||
| ROE, % | ? | -42.2% | -18.8% | 0.44% | 11.4% | -21.9% | -21.9% | |||
| ROA, % | ? | -36.5% | -16.1% | 0.39% | 9.52% | -17.0% | -17.0% | |||
| P/E | ? | -13.1 | -19.9 | 672.3 | 20.1 | -2.71 | 0 | |||
| P/FCF | -13.3 | -16.0 | -23.4 | 92.9 | 12.5 | 0 | ||||
| P/S | ? | 20.9 | 7.56 | 4.20 | 2.61 | 0.48 | 0 | |||
| P/BV | ? | 5.55 | 3.75 | 2.95 | 2.29 | 0.59 | 0 | |||
| EV/EBITDA | ? | -10.4 | -13.6 | -123.8 | 15.8 | 2.21 | 4.62 | |||
| Debt/EBITDA | 2.19 | 4.36 | 49.0 | -9.25 | 4.62 | 4.62 | ||||
| R&D/CAPEX, % | 9 677% | 10 447% | 8 414% | 12 616% | 54 169% | 13 260% | ||||
| CAPEX/Revenue, % | 0.35% | 0.28% | 0.35% | 0.33% | 0.08% | 0.27% | ||||
| Amylyx Pharmaceuticals shareholders | ||||||||||
